Pfizer (PFE)

The most recent research report on the "Hemostat Powder Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts, an

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI® (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors. HYMPAVZI is now indicated in the U.S. for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors.

For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.

They sport recent dividend yields of 3.25%, 6.7%, and a whopping 7.7%.

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.

Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF’3944), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, during a late-breaking expert symposium at the 86th Scientific Sessions of the American Diabetes Association (ADA).

Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting upcoming readouts across its immunology pipeline and a planned Phase 2 asthma study for its lead bispe

Durability, not yield, is the deciding factor.

The most recent research report on the "Avascular Necrosis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts,

These stocks pay between 4.2% and 6.7% in dividends.

Whichever one you choose, you'll need patience before you can see solid returns.

It is finally bouncing back after several challenging years.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

You should consider these strategies if you can't afford to wait out another market crash.

These aren't the most exciting businesses, but they have a lot to offer to long-term investors.

Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

This little-discussed pipeline program could prove to be a big success.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:00 a.m. EDT.

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such a...